Abstract:The gut microbiota influences the effectiveness and side effects of cancer treatments, particularly immunotherapy and associated immune-related complications. This important involvement of the microbiome is supported by the patients receiving antibiotics responding poorly to immunotherapy. Relatively few research has examined the underlying processes, and until recently, data regarding the detection of the microbial organisms that trigger these effects were inconsistent. Since then, a deeper comprehension of the processes of action and taxonomic classification of the relevant species has been attained. It's been demonstrated that certain bacterial species can enhance the body's reaction to immune checkpoint inhibitors through the release of distinct metabolites or products. Nonetheless, in certain patients who are not responding, Gram-negative bacteria may have a dominating suppressive impact. Patients' propensity to react to immunotherapy can be somewhat accurately predicted by machine learning techniques based on their microbiome makeup. Consequently, there has been an increase in interest in modifying the microbiome makeup to enhance patient reaction to medication. Clinical proof-of-concept studies demonstrate that dietary modifications or fecal microbiota transplantation (FMT) might be used therapeutically to increase the efficacy of immunotherapy in cancer patients. Current developments and new approaches for microbiota-based cancer treatments have been emphasized. In conclusion, preclinical research on animals and human clinical trials has made tremendous progress in our understanding of the function of the gut microbiome in health and illness. These investigations have shed light on the effects of food, FMT, probiotics, prebiotics, and microbiome-disease connections. However, there are still a lot of issues and restrictions that must be resolved before this research can be used in real-world clinical settings.

Microbiota and Cytokine Modulation: Innovations in Enhancing Anticancer Immunity and Personalized Cancer Therapies

The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer

Microbiome bacterial influencers of host immunity and response to immunotherapy

Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

The gut microbiome and efficacy of cancer immunotherapy

The gut microbiome modulate response to immunotherapy in cancer

Targeting the gut microbiota for cancer therapy

Exploring the Modulatory Effects of Gut Microbiota in Anti-Cancer Therapy

The Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy

Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect

Microbiota Manipulation as an Emerging Concept in Cancer Therapy

Emerging roles of the gut microbiota in cancer immunotherapy

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

Gut microbiota, an emergent target to shape the efficiency of cancer therapy

The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions

Gut microbiota-mediated immunomodulation in tumor

Effects of microbiota on anticancer drugs: Current knowledge and potential applications

Gold Digging: Searching for Gut Microbiota That Enhances Antitumor Immunity

Role of Gut Microbiome in Cancer Treatment

Gut Microbiome in Modulating Immune Checkpoint Inhibitors.